Richard Lafayette, MD

Richard Lafayette, MD, is a professor of medicine and director of the Glomerular Disease Center at Stanford University Medical Center.

Articles by Richard Lafayette, MD

Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD

ByRichard Lafayette, MD

July 22nd 2026

Richard Lafayette, MD, discusses how atacicept's FDA approval advances BAFF/APRIL targeting in IgA nephropathy.

Atacicept Approval Brings BAFF/APRIL Targeting to IgAN With Richard Lafayette, MD

ByRichard Lafayette, MD

July 20th 2026

ORIGIN 3 investigator brings atacicept approval to BAFF/APRIL targeting to IgAN

Kidney Compass: Atacicept and ORIGIN 3 at Kidney Week 2025, with Richard Lafayette, MD

ByBrendon Neuen, MD,Shikha Wadhwani, MD, MS,Richard Lafayette, MD

November 6th 2025

Discover groundbreaking insights from the ORIGIN 3 study on IgA nephropathy, showcasing promising results and future treatment possibilities.

HCPLive Five at European Renal Association (ERA) Congress 2025

ByFadi Fakhouri, MD, PhD,Jonathan Barratt, MBChB, PhD, FRCP,Richard Lafayette, MD,Rajiv Agarwal, MD, MS,Brendon Neuen, MD,Shikha Wadhwani, MD, MS,Vlado Perkovic, MBBS, PhD

June 25th 2025

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with Richard Lafayette, MD

ByRichard Lafayette, MD

June 6th 2025

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

Progress in IgAN and Future Innovations in Nephrology, with Richard Lafayette, MD

ByRichard Lafayette, MD

April 14th 2025

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

Understanding Atrasentan (Vanrafia) for IgA Nephropathy, with Richard Lafayette, MD

ByRichard Lafayette, MD

April 11th 2025

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Latest Updated Articles

HCPLive Five at European Renal Association (ERA) Congress 2025
June 25th 2025

Richard Lafayette, MD

Articles by Richard Lafayette, MD

Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD

Atacicept Approval Brings BAFF/APRIL Targeting to IgAN With Richard Lafayette, MD

Kidney Compass: Atacicept and ORIGIN 3 at Kidney Week 2025, with Richard Lafayette, MD

HCPLive Five at European Renal Association (ERA) Congress 2025

Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with Richard Lafayette, MD

Progress in IgAN and Future Innovations in Nephrology, with Richard Lafayette, MD

Understanding Atrasentan (Vanrafia) for IgA Nephropathy, with Richard Lafayette, MD

Latest Updated Articles

Trending on HCPLive

Brensocatib Patient Selection Evolves 1 Year After FDA Approval

CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

Why Mentorship Matters Most for Dermatology Trainees

The HCPFive: Top News for Healthcare Providers from the Week of 08/16